Targeting Epithelial-to-Mesenchymal Transition for Breast Cancer Stem Cells Therapeutics

Author(s):  
Shruthi Suthakaran ◽  
Digvijay Singh ◽  
Rohit K. Deshmukh ◽  
Amitava Das
Oncogene ◽  
2013 ◽  
Vol 33 (10) ◽  
pp. 1316-1324 ◽  
Author(s):  
M K Asiedu ◽  
F D Beauchamp-Perez ◽  
J N Ingle ◽  
M D Behrens ◽  
D C Radisky ◽  
...  

2009 ◽  
Vol 69 (7) ◽  
pp. 2887-2895 ◽  
Author(s):  
Marta Santisteban ◽  
Jennifer M. Reiman ◽  
Michael K. Asiedu ◽  
Marshall D. Behrens ◽  
Aziza Nassar ◽  
...  

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Kai Song ◽  
Maryam Farzaneh

AbstractBreast cancer is the second common cancer and the leading cause of malignancy among females overall. Breast cancer stem cells (BCSCs) are a small population of breast cancer cells that play a critical role in the metastasis of breast cancer to other organs in the body. BCSCs have both self-renewal and differentiation capacities, which are thought to contribute to the aggressiveness of metastatic lesions. Therefore, targeting BCSCs can be a suitable approach for the treatment and metastasis of breast cancer. Growing evidence has indicated that the Wnt, NFκB, Notch, BMP2, STAT3, and hedgehog (Hh) signaling pathways govern epithelial-to-mesenchymal transition (EMT) activation, growth, and tumorigenesis of BCSCs in the primary regions. miRNAs as the central regulatory molecules also play critical roles in BCSC self-renewal, metastasis, and drug resistance. Hence, targeting these pathways might be a novel therapeutic approach for breast cancer diagnosis and therapy. This review discusses known signaling mechanisms involved in the stimulation or prevention of BCSC self-renewal, metastasis, and tumorigenesis.


Sign in / Sign up

Export Citation Format

Share Document